Müller, Hermann L. http://orcid.org/0000-0003-4929-9966
Tauber, Maithé http://orcid.org/0000-0002-0363-7862
Lawson, Elizabeth A. http://orcid.org/0000-0001-8619-3349
Özyurt, Jale
Bison, Brigitte
Martinez-Barbera, Juan-Pedro http://orcid.org/0000-0002-5292-7276
Puget, Stephanie
Merchant, Thomas E.
van Santen, Hanneke M. http://orcid.org/0000-0002-6773-6931
Article History
Accepted: 8 March 2022
First Online: 21 April 2022
Competing interests
: This manuscript was composed in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. H.L.M. has received reimbursement of participation fees for scientific meetings and continuing medical education events from Ferring, Lilly, Pfizer, Sandoz/Hexal, Novo Nordisk, Ipsen and Merck Serono, and has received reimbursement of travel expenses from Ipsen and lecture honoraria from Pfizer. M.T. has received reimbursement of participation fees for scientific meetings and continuing medical education events as well as lecture honoraria from Millendo, Pfizer, Novo Nordisk and Merck Serono. M.T. is on the scientific advisory board of OT4B, a pharmaceutical company developing oxytocin treatment in patients with PWS. E.A.L. is on the scientific advisory board and has a financial interest in OXT Therapeutics, a company developing oxytocin-based therapeutics for obesity and metabolic disease. E.A.L.’s interests were reviewed and are managed by MGH and Mass General Brigham (formerly known as Partners Healthcare) in accordance with their conflict of interest policies. J.Ö., B.B., J.-P.M.-B., S.P., T.E.M. and H.M.v.S declare no competing interests.